FDA Advisers Back Replimune Skin Cancer Drug; Shares Surge
Replimune shares surged after FDA advisers backed the company's skin cancer drug, an oncolytic immunotherapy now awaiting a formal regulatory decision.
Topic
Advisory Committee
Topic
Topic
Topic
Replimune shares surged after FDA advisers backed the company's skin cancer drug, an oncolytic immunotherapy now awaiting a formal regulatory decision.